Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 321-330

  Tincati, Camilla ^a   Biasin, Mara ^a   Bandera, Alessandra ^b   Violin, Michela ^a   Marchetti, Giulia ^a   Piacentini, Luca ^a   Vago, Gian Luca ^a   Balotta, Claudia ^a   Moroni, Mauro ^a   Franzetti, Fabio ^a   Clerici, Mario ^a   Gori, Andrea ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INDINAVIR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LAMIVUDINE; LYMPHOTOXIN; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS MESSENGER RNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL KINETICS; CLINICAL ARTICLE; COLON BIOPSY; DRUG TREATMENT FAILURE; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTESTINE LYMPHATIC TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T CELL DEPLETION; TH1 CELL; TH2 CELL; VIRAL PHENOMENA AND FUNCTIONS; VIRUS CLEARANCE; VIRUS LOAD;

ACUTE DISEASE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COLON, SIGMOID; CYTOKINES; DNA, VIRAL; HIV; HIV INFECTIONS; HUMANS; INTESTINAL MUCOSA; LYMPHOID TISSUE; MALE; MIDDLE AGED; RECTUM; RNA, MESSENGER; RNA, VIRAL; TH1 CELLS; TH2 CELLS; TREATMENT FAILURE; YOUNG ADULT;

EID: 67649148057     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol 2003; 21:265-304.
2. + T-cell depletion in HIV disease. Nature 2001; 410:974-979.
3. + T cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-11717.
4. + T-cell depletion at all stages of Simian immunodeficiency virus infection compared to peripheral lymphocytes. J. Virol 1998; 72:6646-6656.
5. Mowat AM. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 2003; 3:331-341.
6. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
7. + T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004; 200:761-770.
8. + T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093-1097.
9. Sankaran S, George MD, Reay E, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary HIV infection is driven by imbalance between immune response and mucosal repair and regeneration. J Virol 2007; 82:538-545.
10. Brenchley JM, Price DA, Douet DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-239.
11. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Gut 1995; 37:524-529.
12. Yerly S, Kaiser L, Perneger TV, et al. et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS 2000; 14:243-249.
13. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-180.
14. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primart HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18:709-718.
15. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006; 194:725-733.
16. Mehandru S, Tenner-Racz K, Racz P, Markowitz M. The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J Allergy Clin Immunol 2005; 116:419-422.
17. Guadalupe M, Sankaran S, George MD, et al. Viral suppression and immune restoration in thg gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236-8247.
18. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med 2006; 3:e484.
19. Carpenter CCJ, Cooper DA, Fischl MA, et al. Updated recommendations of the International AIDS Society-USA panel. JAMA 2000; 283:381-390.
20. Chomczynski P, Sacchi N. Single-step method of RNA, isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
21. Pirissant C, Houbedine LM. An improvement of the single-step method of RNA isolation by acid guanidimum thiocynate-phenol-chloroform extraction. Biotechniques 1990; 8:148-149.
22. Bagnarelli P, Valenza A, Menzo S, et al. Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol 1994; 68:2495-2502.
23. Rusconi S, De Pasquale MP, Milazzo L, et al. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open-label trial. Antivir Ther 1997; 2:39-46.
24. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.
25. Biasin M, Caputo SL, Speciale L, et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis 2000; 182:1365-1374.
26. Ngo-Giang-Huong N, Devean C, Da Silva I, et al. Proviral HIV-1 DNA in subjects followed since primary HIV infection who suppress plasma viral load after 1 year of highly active antiretroviral therapy. AIDS 2001; 15:665-673.
27. Dyrhol-Riise AM, Voltersvik P, Berg OG, Olofsson J, Kleivbo S, Asjo B. Residual human immunodeficiency virus type 1 infection in lympboid tissue during highly active antiretroviral therapy: quantitation and virus characterization. AIDS Res Hum Retroviruses 2001; 17:577-578.
28. Blattner WA, Oursler KA, Cleghorn F, et al. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. J Infect Dis 2004; 189:1793-1801.
29. Lefrere JJ, Roudot-Thorval F, Mariotti M, et al. The risk of disease progression is determined during the first year of human immunodeficiency virus type 1 infection. J Infect Dis 1998; 177:1541-1548.
30. Cressey TR, Lallemant M, Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 2007; 7:333-342.
31. Marchetti G, Gori A, Casabianca A, et al. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART. AIDS 2006; 20:1727-1736.
32. Clerici M, Shearer GM. A TH1->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14:107-111.
33. Clerici M, Balotta C, Selvaggio A, et al. Human immunodeficiency virus (HIV) phenotype and phenotype and interleukin-2/interieukin-10 ratio are associated markers of protection and progression in HIV infection. Blood 1996; 88:574-579.